medigraphic.com
Órgano Oficial del Hospital Angeles Health System

2020, Number 3

<< Back Next >>

Acta Med 2020; 18 (3)

Chronic myelomonocytic leukemia with cutaneous infiltration

Arellano AG, Palomares AP, Aguirre TJ, Santos VG, Domínguez CLG

Language: Spanish
References: 21
Page: 296-301
PDF size: 266.17 Kb.


ABSTRACT

Introduction: Chronic myelomonocytic leukemia is a clonal disorder, in which the change affects the normal development of monocytes, affecting 3/100,000 people after age 65 in the United States. Clinical case: 80-year-old male, with onset of the disease 60 days ago, presenting skin lesions of the nodule-papular-erythematous type, some confluent, with well-defined edges, some purpuric in appearance, disseminated to extremities, respecting face, palms and soles; with 2-cm hepatomegaly and splenomegaly 3 cm below the costal margin; the white formula showed: monocytes 27%, platelets 40,000/mcL. Upon examination of blood smear: metamyelocytes 2%; myelocytes 1%; cytoplasmic vacuolization of monocytes, diffuse basophilia and 1% of normoblasts. Immunophenotypic examination showed: increase of SS (granularity) in the monocyte population, decrease in the expression of CD4 and HLA-DR, overexpression of CD123 and CD16, in addition to aberrant expression of CD56 in 32.8% of total leukocytes; the skin biopsy showed: skin with infiltration by malignant neoplastic cells arranged in nests or laces, with positive myeloperoxidase immunohistochemical marker. Conclusion: Diagnosis of chronic myelomonocytic leukemia with dermic infiltration was established.


REFERENCES

  1. Steensma PD, Padron E. Chronic myelomonocytic leukemia. Update 2019. UpToDate Inc. https://www.uptodate.com.

  2. Alvarado IM, Cardiel SM, García CA, González GL, Hernández RE et al. Consenso de leucemia mieloide crónica por hematólogos del ISSSTE. Rev Hematol Mex. 2016; 17: 34-62.

  3. Rollison DE, Howlader N, Smith MT, Strom SS, Merritt WD, Ries LA et al. Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs. Blood. 2008; 112 (1): 45-52.

  4. Itzykson R, Solary E. An evolutionary perspective on chronic myelomonocytic leukemia. Leukemia. 2013; 27: 1441.

  5. Meggendorfer M, Roller A, Haferlach T, Eder C, Dicker F, Grossmann V et al. SRSF2 mutations in 275 cases with chronic myelomonocytic leukemia (CMML). Blood. 2012; 120: 3080.

  6. Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of tumours of haematopoietic and lymphoid tissues. revised 4th edition, Lyon: International Agency for Research on Cancer (IARC), 2017.

  7. Ávila CO. Infiltración extra-medular en la leucemia mielomonocítica crónica. Rev Cubana Hematol Inmunol Hemoter. 2008. Disponible en: http://scielo.sld.cu/scielo. php?script=sci _arttext&pid=S0864-02892008000300009&lng=es.

  8. Duguid JK, Mackie MJ, McVerry BA. Skin infiltration associated with chronic myelomonocytic leukaemia. Br J Haematol. 1983; 53: 257-264.

  9. McCollum A, Bigelow CL, Elkins SL, Hardy CL, Files JC. Unusual skin lesions in chronic myelomonocytic leukemia. South Med J. 2003; 96: 681-684.

  10. Mathew RA, Bennett JM, Jijun LJ, Komrokji RS, Lancet JE, Naghashpour M et al. Cutaneous manifestations in CMML: indication of disease acceleration or transformation to AML and review of the literature. Leuk Res. 2012; 36: 72-80.

  11. Mahmood S, Cooper A, Ireland R, Pocock C. Leukaemia cutis with chronic myelomonocytic leukaemia. Br J Haematol. 2009; 147: 413-416.

  12. Peña RA, Domínguez CHJ, Méndez FS. Leucemia cutis (LC): características clínicas de 27 pacientes mexicanos y una breve revisión de la literatura. Gac Med Mex. 2016; 152: 703-710.

  13. Pulido N, Medina G, Palomino N, Peralta F. Manifestaciones cutáneas de las leucemias. Rev Med Inst Mex Seguro Soc. 2015; 53 Supl 1: S30-35.

  14. Elena C, Gallì A, Such E, Meggendorfer M, Germing U, Rizzo E et al. Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia. Blood. 2016; 128: 1408.

  15. Yoshida K, Sanada M, Shiraishi Y, Nowak D, Nagata Y, Yamamoto R et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature. 2011; 478: 64-69.

  16. Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016; 127: 2391.

  17. Selimoglu-Buet D, Wagner-Ballon O, Saada V, Bardet V, Itzykson R, Bencheikh L et al. Characteristic repartition of monocyte subsets as a diagnostic signature of chronic myelomonocytic leukemia. Blood. 2015; 125: 3618-3626.

  18. Patnaik MM, Padron E, LaBorde RR, Lasho TL, Finke CM, Hanson CA et al. Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomes. Leukemia. 2013; 27: 1504-1510.

  19. Park S, Labopin M, Yakoub-Agha I, Delaunay J, Dhedin N, Deconinck E et al. Allogeneic stem cell transplantation for chronic myelomonocytic leukemia: a report from the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire. Eur J Haematol. 2013; 90: 355-364.

  20. Antonioli E, Guglielmelli P, Pieri L, Finazzi MC, Rumi E, Martinelli V et al. Hydroxyurea-related toxicity in 3,411 patients with Ph’-negative MPN. Am J Hematol. 2012; 87: 552-554.

  21. Santini V, Allione B, Zini G, Gioia D, Lunghi M, Poloni A et al. A phase II, multicentre trial of decitabine in higher-risk chronic myelomonocytic leukemia. Leukemia. 2018; 32: 413-418.




2020     |     www.medigraphic.com